ライフサイエンスコーパス: blood test

1 mmonly used platelet parameters from routine blood test.

2 quality of life, anxiety/depression, or any blood test.

3 creening test of which 83% chose the Septin9 blood test.

4 strated the feasibility of an IBM diagnostic blood test.

5 he improved safety of a noninvasive maternal blood test.

6 help identify cancer patients using a simple blood test.

7 st) is a novel animal specific TB diagnostic blood test.

8 ous negatives and whether a GP had ordered a blood test.

9 analysis that included fecal immunochemical blood test.

10 nclusion, MPV is easily available in routine blood test.

11 nclusion, PDW is easily available in routine blood test.

12 /- 0.8 y using standard procedures including blood tests.

13 r the development of early-stage, pan-cancer blood tests.

14 llary investigations, mainly MRI and routine blood tests.

15 n imaging, and cerebrospinal fluid (CSF) and blood tests.

16 ata were collected from routine preoperative blood tests.

17 d for a medical consultation and a series of blood tests.

18 erformance characteristics than fecal occult blood tests.

19 84 years in average health with fecal occult blood tests.

20 assessed using standard procedures including blood tests.

21 le of participants who returned annually for blood tests.

22 ment reflected in an electrocardiogram or in blood tests.

23 be reliably quantified in vivo using regular blood tests.

24 treatment recommendations using non-invasive blood tests.

25 tically investigated using sputum, urine and blood testing.

26 tially reduced sensitivity compared to whole-blood testing.

27 nual or biennial screening with fecal occult-blood testing.

28 ometry), comprehensive echocardiography, and blood testing.

29 ed by monitoring response to therapy through blood testing.

30 ars, cholesterol screening, and fecal occult blood testing.

31 d referred as many as 5 for interviewing and blood testing.

32 ted a random sample of 3,200 individuals for blood testing.

33 Twenty-six cancers were detected by blood testing.

34 be lower than that with guaiac fecal occult blood testing.

35 tients had 2 consecutively positive ctHPVDNA blood tests, 15 of whom developed biopsy-proven recurren

36 thy women aged 70-74 years with fecal occult blood tests, 431 women aged 75-79 years in poor health w

37 The participants perceived blood testing (49.9%) to be more accurate than OF testin

38 s (11.8%), or a positive result from a fecal blood test (5.5%).

39 atio, 1.32; 95% CI, 1.19-1.45), but not with blood testing (53% vs 45%; aOR, 1.18; 95% CI, 0.96-1.46)

40 90 selected the Septin9 blood test (83%), 16 selected a stool test (15%) and 3 r

41 future trajectories for clinically relevant blood tests(9).

42 Non-MRI techniques, including baseline blood tests, abdominal ultrasonography in children, mamm

43 related adverse events, serious arrhythmias, blood test abnormalities, or death.

44 SPSTF found adequate evidence that capillary blood testing accurately identifies children with elevat

45 Many common clinical blood tests actually include thousands of single-cell me

46 ents with syncope who had a 30-day SAE, this blood test added little new information to the CSRS.

47 , 2) FIT: annual immunochemical fecal occult blood test age 40-75 years, 3) gFOBT: annual guaiac-base

48 , 3) gFOBT: annual guaiac-based fecal occult blood test age 40-75 years, and 4) COL: 10-yearly colono

49 hospital based on seven routinely undertaken blood tests (albumin, creatinine, haemoglobin, potassium

50 nction between LTBI and active TB based on a blood test alone.

51 ble substitutes for traditional fecal occult blood testing, although modeling may be needed to determ

52 ear test, 2) a mammogram, 3) a faecal occult blood test and 4) a prostate specific antigen test.

53 1 healthy young Caucasians whose 35 clinical blood test and anthropometric indices matched the medica

54 (95% CI: 34.2%-40.1%) would have received a blood test and appropriate antimalarial (44.4% for the 2

55 antly with worseing pathology, findings from blood test and clinical outcomes; rates of conversion an

56 t validated risk adjustment Tree model using blood test and NEWS taken within +/-24 hours of admissio

57 Marked eosinophilia in a blood test and sputum, poorly defined centrilobular nodu

58 od that PE is present, followed by a D-dimer blood test and/or CTPA.

59 All subjects received a demographic survey, blood testing and abdominal ultrasonography (US).

60 improve patient compliance with fecal occult blood testing and colorectal cancer screening in general

61 cal trials to reduce mortality: fecal occult blood testing and flexible sigmoidoscopy.

62 in which they were offered routine clinical blood testing and ileocolonoscopy; 322 were screened by

63 Participants had repeat blood testing and were administered a questionnaire on r

64 y than nonphysicians to undergo fecal occult blood testing and were more likely to undergo colonoscop

65 All patents had fasting blood tests and anthropometric measures at the time of l

66 lectron beam computed tomography and fasting blood tests and cardiovascular risk factors were obtaine

67 Initial blood tests and history were thought possibly to suggest

68 and after 1 year, patients underwent routine blood tests and measurement of CAC, BMD, and novel serum

69 We explored the use of routine blood tests and national early warning scores (NEWS) rep

70 3248 emergency admissions with a full set of blood tests and NEWS with an in-hospital mortality of 5.

71 s to assess the relationship between routine blood tests and outcomes using a Cox proportional hazard

72 Routine blood tests and routine lumbar punctures are usually unn

73 events (version 4.0) on the basis of serial blood tests and the attending physician's report.

74 isease in the differential of abnormal liver blood tests and to be aware of the clinical implications

75 (about 30%) did not have a full set of index blood tests and/or NEWS and so were not included in our

76 ue to withdrawal based on refusal to provide blood tests) and were not included in the analyses.

77 rasound, or magnetic resonance imaging), any blood test, and ED length of stay, adjusted for visit ac

78 rwent PET-CT imaging based on false-positive blood tests, and 0.22% underwent a futile invasive diagn

79 ons were associated with older age, abnormal blood tests, and abnormal vital signs.

80 48-h ambulatory electrocardiography, fasting blood tests, and clinical examination.

81 ectrocardiograms, 24-hour Holter monitoring, blood tests, and completion of Minnesota Living with Hea

82 history of heavy alcohol use, findings from blood tests, and exclusion of other liver diseases by bl

83 re (blood pressure measurement, urine tests, blood tests, and information on complications), as well

84 ceived a liver biopsy, lifestyle assessment, blood tests, and QOL tools, including the Chronic Liver

85 ults underwent whole-body 3DO and DXA scans, blood tests, and strength assessments in the Shape Up!

86 Clinical examination, blood tests, and upper endoscopy were done before random

87 aging (aOR, 1.21; 95% CI, 0.96-1.53), or any blood test (aOR, 1.02; 95% CI, 0.79-1.33), but had longe

88 A variety of methodological approaches to blood testing are under development, with different leve

89 Routine blood tests are an integral part of clinical medicine an

90 No clinical blood tests are available for diagnosis or disease monit

91 Many blood tests are moderately useful for identifying clinic

92 Blood tests are more readily available, with less cost a

93 Blood tests are needed to identify steroid-resistant (SR

94 or colonoscopy with a positive faecal occult blood test as part of the UK national bowel cancer scree

95 groups in the frequency of abnormalities on blood tests assessing potential metabolic disturbances.

96 acceptability include the perception that a blood test at health centre level represents improvement

97 Infants of infected women had blood tested at 0 and 1 month by microscopy, PCR and imm

98 mptom assessment, clinical examinations, and blood tests at 3- to 4-month intervals for 2 years, with

99 Relevant blood tests at this stage revealed a C-reactive protein

100 P-gp activity in the blood-brain barrier and blood-testes barrier.

101 ly in this organ, given the existence of the blood-testes barrier.

102 reliminary results of PanSeer, a noninvasive blood test based on circulating tumor DNA methylation, o

103 A noninvasive whole-blood test based on gene expression and demographic char

104 Here, we report a blood test, based on the simultaneous quantization of fo

105 Blood test-based measures or left ventricular ejection f

106 32.5% (95% CI: 30.3%-34.7%) received both a blood-test-based diagnosis and an appropriate antimalari

107 Additional data from fasting blood tests better identified those at extreme risk.

108 t might form the foundation for new clinical blood tests, but to date their contribution to the diagn

109 We performed weekly surveillance blood testing by quantitative polymerase chain reaction

110 dipstick testing, urine cultures, and simple blood tests can provide direction.

111 A nonsputum blood test capable of predicting progression of healthy

112 rticipants collected 3 stools, smeared fecal blood test cards and used same-day shipment to a central

113 example, simplifying access to fecal occult blood test cards), or made system-level changes (for exa

114 NAlater Stabilization Solution, fecal occult blood test cards, and fecal immunochemical test tubes).

115 dergo limited occult-cancer screening (basic blood testing, chest radiography, and screening for brea

116 These include: general blood test, colonoscopy, colon biopsy, medical imaging a

117 These data demonstrate that multicancer blood testing combined with PET-CT can be safely incorpo

118 ntions, and expands on the findings of prior blood tests conducted on this group of patients.

119 Blood tests confirmed no evidence of autoimmune or viral

120 The stool occult blood test continues to be utilized for reasons other th

121 Since baseline blood tests correlated with week 117 treatment outcomes,

122 A simple blood test could aid the front-line physician in this ta

123 ggest that deep learning analysis of routine blood tests could complement or even replace the current

124 ed the feasibility and safety of multicancer blood testing coupled with positron emission tomography-

125 Blood tests demonstrated high specific IgE (>=50UA/ml) a

126 The proportion of children with a blood test diagnosis and an appropriate antimalarial ran

127 dren with a malaria diagnosis who received a blood test diagnosis and an appropriate antimalarial.

128 Receipt of a blood test diagnosis and appropriate antimalarial was po

129 ren with a malaria diagnosis received both a blood test diagnosis and appropriate antimalarial.

130 positive titer >/=1 in 40, cholestatic liver blood tests, diagnostic or compatible liver histology).

131 Safety assessment included blood tests, documentation of adverse events at regular

132 whether PSP is superior to other established blood tests (e.g. White Blood Count, Neutrophils or C -

133 a standardized baseline assessment with CMR, blood test, echocardiography, and 6-minute walk test and

134 More blood tests (eg, total cholesterol, odds ratio [OR] 1.88

135 Additional diagnostic tests include blood tests (erythrocyte sedimentation rate, ESR; C-reac

136 r high-sensitivity guaiac-based fecal occult blood testing every 2 years, colonoscopy every 10 years,

137 All patients underwent blood tests, exhaled nitric oxide (FeNO), sputum inducti

138 Conventional blood tests fail to offer real-time unambiguous visualiz

139 ing with sensitive guaiac-based fecal occult blood testing, fecal immunochemical testing (FIT), multi

140 synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six cla

141 atus using 3 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years, or co

142 providers use only the digital fecal occult blood test (FOBT) as their primary screening test.

143 t for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low levels of

144 The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening

145 The Fecal Occult Blood Test (FOBT) is one of the diagnostic modalities in

146 graphy, Papanicolaou tests, and fecal occult blood testing (FOBT) but not colonoscopy, flexible sigmo

147 py or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, colonoscopy, or

148 s either sensitive unrehydrated fecal occult blood testing (FOBT) or fecal immunochemical testing (FI

149 only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

150 cancer by use of guaiac-based faecal occult blood tests (FOBT) reduces disease-specific mortality.

151 ng Programme (asymptomatic but faecal occult blood testing [FOBt] positive).

152 Rates of patient completion of fecal occult blood tests (FOBTs) are often low.

153 Consecutive rounds of fecal occult blood tests (FOBTs) are used to screen for colorectal ca

154 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or colonosc

155 These initial studies provide a prototype blood test for diagnosis of vCJD in symptomatic individu

156 Anemia was measured with a blood test for hemoglobin.

157 A blood test for HVPG could be performed in cirrhosis pati

158 82% of the original 1133 subjects underwent blood test for IgE and answered the questionnaire, respe

159 Currently, a blood test for lung cancer does not exist.

160 tivity diary that was temporally linked to a blood test for measurement of 25(OH)D concentration.

161 suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshol

162 A blood test for PAD, if sufficiently sensitive and specif

163 findings show that PMCA might be useful as a blood test for routine, live animal diagnosis of CWD.

164 t detection assay, developed originally as a blood test for vCJD, for the detection of disease-associ

165 The result of a blood test for vCJD, the Direct Detection Assay for vCJD

166 Women randomised to the MMS group had their blood tested for CA125 and those randomised to the USS g

167 ubjects kept a 3-d food record and had their blood tested for metabolic risk factors.

168 Of these, 749 (77%) had blood tested for S. pneumoniae.

169 Blood testing for endogenous small metabolites to determ

170 ed optical transducer to allow point-of-care blood testing for risk stratifications of cardiac patien

171 Inexpensive blood tests for diabetes, thyroid dysfunction, and vitam

172 Since thyroglobulin, no new blood tests for differentiated thyroid cancer (DTC) have

173 isit included history, physical examination, blood tests for renal, lipid, glucose profiles, and 24-h

174 cy studies reporting on the use of fecal and blood tests for the evaluation of adult patients with fu

175 Most PCPs have access to blood tests for total and specific IgE.

176 less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and colonoscopy for

177 e tools (clinical decision rules and D-dimer blood tests) for patients with low pretest probability a

178 Two consecutively positive ctHPVDNA blood tests had a PPV of 94% (95% CI, 70% to 99%).

179 A series of blood tests had recently been obtained (Table).

180 This simple blood test has the potential to transform prostate cance

181 Many blood tests have been proposed as alternatives to liver

182 ults of tests for inflammation (stool occult blood testing [Hemoccult], fecal leukocytes, fecal lacto

183 prevalent TB is potentially important, as no blood test hitherto has been suggested as having the uti

184 ollection, physical examination, biochemical blood tests, hormone levels, transthoracic Doppler echoc

185 5% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) than those wit

186 nce interval (CI): 1.17, 2.19), fecal occult blood tests (HR=1.31, 95% CI: 1.12, 1.53), screening mam

187 annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemical test

188 with respect to 116 traits assessed through blood tests, hypertonic saline challenge tests, question

189 to detect acute dengue illnesses, and annual blood testing identifies subclinical seroconversions.

190 We tested a novel simple and rapid blood test in 30 patients with GLUT1-DS with predominant

191 ts was defined by a record of a fecal occult blood test in the past 2 years, flexible sigmoidoscopy i

192 sis using additional adjustment for selected blood tests in a subgroup of 182,792 ICU episodes lowere

193 needed for primary care on the use of liver blood tests in detection of early disease and the need f

194 Blood tests included cytokines, clotting factors, apolip

195 Blood tests included measurements of 25-hydroxyvitamin D

196 An extensive series of blood tests including serum amylase were serially checke

197 Blood tests, including vitamin E, B(12), folate, lead, a

198 Blood tests indicated no evidence of toxicity.

199 ctal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55% of th

200 accurately classified patients with a single blood test into rule-out or rule-in categories: Net Recl

201 (1) Dichotomise the blood tests into normal/abnormal or (2) use the actual v

202 T-qPCR however, this enzyme-free, isothermal blood test is amenable to incorporation into low-cost po

203 The general blood test is both the most ordered and most refused too

204 n resistance reflected in R values from this blood test is higher for patients with AD, DM2, and FTD

205 enge because an accurate, minimally invasive blood test is lacking.

206 ere a highly reliable and minimally invasive blood test is lacking.

207 d by offering non-invasive tests, and that a blood test is the preferred option should be validated i

208 Fecal occult blood testing is a popular screening test because of its

209 ves and high false negatives of fecal occult blood testing lead to high costs and low cost-effectiven

210 patients included neurological examination, blood tests, magnetic resonance imaging (MRI), and dual-

211 A new 1,3 beta-glucan blood test may assist is the definition of invasive fung

212 with IPMNs and suggest that an lncRNA-based blood test may have utility as a diagnostic adjunct for

213 evidence indicates that available fecal and blood tests may play a role in the diagnostic workup of

214 The rate of inadequate blood-test monitoring (composite of 2 indicators) reduce

215 posed to hazardous prescribing or inadequate blood-test monitoring at the start of the intervention w

216 ntially hazardous prescribing and inadequate blood-test monitoring in general practices.

217 ated to hazardous prescribing and inadequate blood-test monitoring of medicines 6 months after the in

218 ntially hazardous prescribing and inadequate blood-test monitoring, comparing observed rates post-int

219 ial screening with guaiac-based fecal occult blood testing (n = 419,966) showed reduced CRC-specific

220 nical lab tests between one company offering blood tests obtained from finger prick (Theranos) and 2

221 achieving effective cancer management, with blood tests offering a minimally invasive, safe, and sen

222 n pathways altered by insulin using a single blood test offers confidence in the current approach.

223 Further blood testing often reveals a range of changes affecting

224 The effect of screening with fecal occult-blood testing on colorectal-cancer mortality persists af

225 y, systemic inflammatory biomarkers, ex vivo blood tests on immunoreactivity to lipopolysaccharide (L

226 Staging can be performed using blood testing only.

227 However, current clinical blood tests only measure the total concentration of ALP

228 cancer include sensitive guaiac fecal occult blood test or fecal immunochemical test.

229 utive patients with a positive faecal occult blood test or previous adenomas undergoing surveillance

230 mmend for or against routine use of hormonal blood tests or hormonal treatment in the management of p

231 ts taking biotin supplements before ordering blood tests or when interpreting results.

232 ), or having undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29).

233 gs from screening tests (urinary dipstick or blood tests), or when symptoms become severe.

234 , using clinical interviews, questionnaires, blood tests, or a combination of these methods.

235 cal and systemic toxicity was assessed using blood tests, organ weights, and histology.

236 Among blood-tested participants included at age 38 years, mean

237 s indicated that the AmpliSens DBS and whole-blood tests performed equally well and were comparable t

238 rrelated linearly (r .47) with the number of blood tests performed in both study periods.

239 C tuberculosis (TB) test if symptomatic, POC blood tests, physical exam, education, counseling, and a

240 Reasons for blood test preference included convenience of an office

241 rs in addition to the biennial faecal occult blood testing programme offered to all individuals aged

242 Elevated cholestatic enzymes on blood tests raise suspicion of these entities.

243 In randomized trials, fecal occult-blood testing reduces mortality from colorectal cancer.

244 c indications, such as positive fecal occult blood test result (OR, 0.33; 95% CI, 0.19-0.57), surveil

245 art of clinical medicine and in interpreting blood test results clinicians have two broad options.

246 Dichotomising routine blood test results is less accurate in predicting in-hos

247 Pertinent blood test results showed an increased white blood cell

248 Pertinent blood test results showed an increased white blood cell

249 antibody, and angiotensin-converting enzyme blood test results were negative.

250 Biomarkers based on standard blood test results would be useful in research, drug dev

251 Following analysis of recent and previous blood test results, a diagnosis of chronic benign neutro

252 uding demographic details, weight follow-up, blood test results, and information on medications and c

253 ta, clinical manifestations at presentation, blood test results, EUS and ERCP findings, and clinical

254 We used routine blood test results, length of hospital stay, and 30-day

255 s of asymptomatic adults with positive fecal blood test results.

256 Midlands, England, with a full set of index blood tests results (albumin, creatinine, haemoglobin, p

257 Blood tests revealed a remarkable increase in eosinophil

258 Blood tests revealed significantly decreased erythrocyte

259 the first screening round of a faecal occult blood test screening programme in a single geographical

260 Routine blood tests showed lactic acidosis and mild elevation of

261 Blood tests showed mild anemia, neutrophilic leukocytosi

262 illustrated efficacy, including fecal occult blood testing, sigmoidoscopy and colonoscopy.

263 nt comprehensive screening with stool occult blood testing, standard upper gastrointestinal endoscopy

264 This represents the first prostate cancer blood test that can predict which patients will have a h

265 We conclude that a blood test that measures unmethylated INS DNA serves as

266 Recently, a novel in vitro blood test that provides an overall measure of calcifica

267 FN-gamma release assays (IGRAs) are in vitro blood tests that measure T-cell release of IFN-gamma aft

268 tal growth restriction, or abnormal maternal blood tests that were suggestive of disease (such as thr

269 colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitarg

270 al for the development of metabolomics-based blood tests, the results confirmed that the RRMS vs. SPM

271 From the subsample annual blood test, there was no case of hypercalcemia in the vi

272 TSHR mRNA also represents a new blood test to aid assessment of disease status in thyroi

273 Currently, there is no blood test to predict the underlying pathology or distin

274 adaptation of an established vCJD diagnostic blood test to urine.

275 0 persons with SCI for 4 months with monthly blood testing to quantify the lipoprotein profile (e.g.,

276 Blood tests to detect circulating tumor cells (CTC) offe

277 eat strategy, in which individuals are given blood tests to determine whether they are chronically in

278 Currently, rapid blood tests to diagnose EBOV infection include the antig

279 r addressing the limitations of finger-prick blood testing toward tracking glucose trends over time,

280 acteristics, cause of disease, liver-related blood tests, tumour characteristics, treatments, last fo

281 ing 10,050 emergency admissions with routine blood tests undertaken within 24 hours of admission.

282 ces to merit case-note review and diagnostic blood tests, unless an obvious explanation is found.

283 A blood test using attenuated total reflection (ATR)-Fouri

284 We devised guidelines to optimize blood tests utilization, and designed this study to quan

285 Further research into the use of actual blood test values in clinical decision making is require

286 ted that the gene expression profiling (GEP) blood test was noninferior to EMB between 6 and 60 month

287 Initial blood testing was unremarkable, with a haemoglobin level

288 r the laboratory-based model, which required blood testing, we used standard risk factors to assess r

289 py, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 1000 person-year

290 Positive blood tests were independently confirmed by a diagnostic

291 Platelet levels in routine blood tests were monitored for 3 d after injection to as

292 Blood tests were normal, except for the elevation of pla

293 Blood tests were obtained at trial completion.

294 Fasting blood tests were performed at regular time intervals dur

295 ces performed for routine blood sampling; no blood tests were performed solely for the purpose of the

296 n the transcriptional signatures measured by blood tests were readily detectable just 2 weeks after t

297 0 mL/min/1.73 m2 on two consecutive previous blood tests were recruited from 32 primary care practice

298 Colonoscopy and blood tests were the "first line" diagnostic tools.

299 and muscle degeneration, and develop an IBM blood test with high diagnostic accuracy.

300 markers are obtained intermittently through blood testing with long delay.